Stock Financial Ratios


EYEG / Eyegate Pharmaceuticals Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price1.09
Volume104,700.00
Market Cap ($M)11.48
Enterprise Value ($M)1.39
Book Value ($M)-0.33
Book Value / Share-0.04
Price / Book-36.20
NCAV ($M)2.42
NCAV / Share0.27
Price / NCAV5.00
Income Statement (mra) ($M)
Revenue0.67
EBITDA0.00
Net Income-13.34
Balance Sheet (mrq) ($M)
Cash & Equivalents11.76
Cash / Share1.33
Assets18.31
Liabilities13.74
Quick Ratio0.57
Current Ratio0.57
Management Effectiveness (mra)
Return on Invested Capital (ROIC)40.51
Return on Assets (ROA)-0.73
Return on Equity (ROE)40.51
Identifiers and Descriptors
CUSIP30233M107
Central Index Key (CIK)1372514
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Share Statistics
Common Shares Outstanding (M)17.20
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Deferred Income Tax Liabilities Per Share0.17
Inventory Finished Goods Per Share0.00
Cash And Equivalents Per Share1.33
Liabilities Other Non Current Per Share0.00
Equity Per Share0.52
Intangibles Per Share0.00
Retained Earnings Per Share-9.60
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Assets Other Non Current Per Share0.04
Liabilities And Stock Equity Per Share2.07
Additional Paid In Capital Per Share10.09
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Assets Per Share2.07
Cash Per Share1.33
Assets Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Inventory Per Share0.00
Liabilities Current Per Share1.25
Assets Current Per Share1.41
Liabilities Per Share1.56
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Net Per Share0.00
Debt Per Share0.00

Related News Stories

Burns & Levinson Partner Joseph Maraia Named to "Intellectual Property Trailblazers" List by The National Law Journal

2017-07-06 prnewswire
BOSTON, July 6, 2017 /PRNewswire/ -- Burns & Levinson announced today that partner Joseph Maraia has been named to the "Intellectual Property Trailblazers" list by The National Law Journal (NLJ). According to the NLJ, each of the attorneys recognized have "shown a deep passion and perseverance in pursuit of their mission, having achieved remarkable successes along the way."

BRIEF-Innoven Partenaires reports a 9.5 pct stake in Eyegate Pharmaceuticals

2017-06-16 reuters
* Innoven Partenaires S.A. reports a 9.5 percent stake in Eyegate Pharmaceuticals Inc as of June 14 - SEC filing (0-1)

BRIEF-Empery Asset Management reports 9.22 pct passive stake in Eyegate Pharmaceuticals

2017-06-14 reuters
* Empery Asset Management LP reports a 9.22 percent passive stake in Eyegate Pharmaceuticals Inc as of June 9, 2017 - SEC filing Source text: (bit.ly/2saWqql) Further company coverage: (0-1)

Valeant (VRX) Down 4% Since Earnings Report: Can It Rebound?

2017-06-14 zacks
A month has gone by since the last earnings report for Valeant Pharmaceuticals International, Inc. (VRX - Free Report) . Shares have lost about 4% in that time frame, underperforming the market.

Biotech Forum Daily Digest: Analysts Warming To Mylan; Spotlight On Seres Therapeutics

2017-05-22 seekingalpha
The biotech sector fell largely in line with the overall market last week and remains trapped in a narrow trading range. (0-1)

CUSIP: 30233M107